20 December 2022
Cizzle Biotechnology Holdings plc
("Cizzle" or the "Company")
Update re. timing of Admission
Cizzle Biotechnology Holdings plc, the UK based diagnostics developer, announces that further to the announcement made by the Company on 19 December 2022, the Company has become aware that the next available listing hearing date for the Admission of the shares pursuant to the Subscription is 4 January 2023. It is now therefore expected that Admission will become effective at 8.00 a.m. on 5 January 2023.
Words defined in this announcement shall have the same meaning as in the announcement released on 19 December 2022.
Enquiries:
| Cizzle Biotechnology Holdings plc | Via IFC Advisory |
| Allan Syms (Executive Chairman) | |
| Allenby Capital Limited | +44(0) 20 3328 5656 |
| John Depasquale | |
| Alex Brearley | |
| Novum Securities Limited | +44(0) 20 7399 9400 |
| Colin Rowbury Jon Bellis | |
| IFC Advisory Limited | +44(0) 20 3934 6630 |
| Tim Metcalfe | |
| Florence Chandler | |
About Cizzle Biotechnology
Cizzle Biotechnology is also developing a blood test for the early detection of lung cancer. Cizzle Biotechnology is a spin- out from the University of York, founded in 2006 around the work of Professor Coverley and colleagues. Its proof-of-concept prototype test is based on the ability to detect a stable plasma biomarker, a variant of CIZ1 known as CIZ1B. CIZ1 is a naturally occurring cell nuclear protein involved in DNA replication, and the targeted CIZ1B variant is highly correlated with early-stage lung cancer. For more information, please see https://cizzlebiotechnology.com You can also follow the Company through its twitter account @CizzlePlc and on LinkedIn.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.